Analysts at BMO Capital Markets lifted their target price on shares of Zoetis Inc (NYSE:ZTS), from $35.00 to $37.00 in a research report issued to clients and investors on Thursday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective indicates a potential upside of 13.99% from the company’s current price. Zoetis Inc (NYSE:ZTS), net profit margin is 11.40% and weekly performance is -0.95%. On last trading day company shares ended up $32.24. Analysts mean target price for the company is $36.08. Zoetis Inc (NYSE:ZTS), distance from 50-day simple moving average (SMA50) is 4.37%.
On June, 11, 2014, Mylan Inc (NASDAQ:MYL), announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott’s Actonel Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Mylan Inc (NASDAQ:MYL), advanced 0.46% in last trading session and ended the day on $51.87. MYL, Gross Margin is 44.80% and its return on assets is 4.50%. Mylan Inc (NASDAQ:MYL), quarterly performance is 6.77%.
Actavis plc (NYSE:ACT), has earned a consensus recommendation of “Buy” from the twenty-two analysts that are presently covering the company, Analyst RN reports. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $226.35. Actavis plc (NYSE:ACT), shares moved up 0.57% in last trading session and was closed at $224.09, while trading in range of $221.61 – 225.25. Actavis plc (NYSE:ACT), year to date (YTD) performance is 33.39%.
ON June 24, 2014, Forest Laboratories, Inc. (NYSE:FRX), announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD). In two flexible-dose and one fixed-dose GAD trials, patients who received vilazodone demonstrated statistically significant improvement from baseline in the Hamilton Rating Scale for Anxiety (HAM-A) total score versus placebo at week 8, the primary endpoint. Forest Laboratories, Inc. (NYSE:FRX), ended the last trading day at $99.96. Company weekly volatility is calculated as 1.59% and price to cash ratio as 12.66. Forest Laboratories, Inc. (NYSE:FRX), showed a positive weekly performance of 3.10%.
On June 24, 2014, Avanir Pharmaceuticals Inc (NASDAQ:AVNR), announced that data related to the safety and efficacy of AVP-825, a Breath-Powered™ Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society’s 56th Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath-Powered™ delivery technology. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), net profit margin is -74.00% and weekly performance is -0.18%. On last trading day company shares ended up $5.40. Analysts mean target price for the company is $9.33. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), distance from 50-day simple moving average (SMA50) is 13.45%.